Abbott Laboratories (Abbott), a world-leading medical devices and healthcare company, is one of the leaders in Covid-19 testing with its three diagnostic PCR tests: the ID NOW, m2000, and Alinity m.

Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The North Chicago company said ...

Abbott Laboratories is hoping to broaden its reach by appealing to healthy consumers with its new wearable device called Lingo. CEO Robert Ford said Abbott will continue to solve medical problems, ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

The maker of a rapid coronavirus test widely used across the United States and distributed by the federal government has warned that its device can produce false negatives if a special solution is ...

The S&P 500 has performed well in 2023, but healthcare stocks have lagged behind. Abbott Laboratories continues to lap difficult comparable quarterly earnings reports, but the core business has been ...

In a decisive move to fund one of its most significant strategic acquisitions in recent years, Abbott Laboratories has launched a massive $20 billion bond offering. The proceeds are earmarked to ...

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on ...

A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...